

Effect of High-Dose Vitamin D Therapy on Bone Mineral Density and Anastrozole-Induced Musculoskeletal Pain

Presentation discussed in this issue:

Rastelli AL et al. **A double-blind, randomized, placebo-controlled trial of high dose vitamin D therapy on musculoskeletal pain and bone mineral density in anastrozole-treated breast cancer patients with marginal vitamin D status.** San Antonio Breast Cancer Symposium 2009; **Abstract 803**.

Slides from a presentation at SABCS 2009

A Double-Blind, Randomized, Placebo-Controlled Trial of High-Dose Vitamin D Therapy on Musculoskeletal Pain and Bone Mineral Density in Anastrozole-Treated Breast Cancer Patients with Marginal Vitamin D Status

Rastelli A et al.

SABCS 2009; Abstract 803.

Research
To Practice®

Introduction

- Musculoskeletal (MS) pain and bone loss are known adverse effects of aromatase inhibitors.
- A high prevalence of vitamin D deficiency/insufficiency has been previously reported in patients with breast cancer complaining of MS pain (SABCS 2004:Abstract 443).
- Anecdotal evidence suggests that MS pain induced by aromatase inhibitors can be relieved by weekly supplementation with high doses of vitamin D.
- **Current study objectives:**
 - Assess if high-dose vitamin D (HDD) supplementation improves anastrozole-induced musculoskeletal symptoms.
 - Assess if vitamin D supplementation may favorably impact the bone mineral density (BMD) of patients on anastrozole.

Rastelli A et al. SABCS 2009;Abstract 803.

Research
To Practice®

Trial Design

Eligibility (n=60)

Postmenopausal, hormone receptor-positive, stage I to IIIB

Marginal 25-OH vitamin D level (10-29 ng/mL)

24-hr urine calcium excretion \leq 250 mg/day

MS pain symptoms that began or worsened since initiation of anastrozole therapy

R

Ca (1,000 mg/day) + Vitamin D3 (400 IU/day) + Vitamin D2 (50,000 IU/wk)*

*8 wks: if 25-OH VitD 20-29 ng/mL
16 wks: if 25-OH VitD 10-19 ng/mL
Followed by monthly vitamin D (50,000 IU) or placebo

Ca (1,000 mg/day) + Vitamin D3 (400 IU/day) + Placebo (once/wk)*

Pain and impairment evaluated: baseline, 2, 4, and 6 mos
Femoral/Neck BMD evaluated: baseline and 6 mos

Rastelli A et al. SABCS 2009;Abstract 803.

Research
To Practice®

Participants in Each Arm at Each Time Point

	High-dose Vitamin D	Placebo
Number of patients randomized	30	30
Number of discontinuations over 6 mos*	9	4
Number of patients completing 2 mos	28	29
Number of patients completing 4 mos	22	28
Number of patients completing 6 mos	21	26

*Reasons for discontinuation include: continued muscle pain, high serum or urinary calcium, or development of adverse event (Placebo arm: 1 diarrhea, 1 non-treatment related arterial thrombosis).

Rastelli A et al. SABCS 2009;Abstract 803.

Research
To Practice®

Effect of High-Dose Vitamin D on Pain and BMD

- At 2 months, patients receiving HDD reported lower scores on pain-related questions on BPI ($p=0.009$) and FIQ surveys ($p=0.01$).
- A trend for improved scores for walking and climbing steps on the Health Assessment Questionnaire (HAQ) was reported in patients administered HDD (at 2 mos, $p=0.04$).
- Preliminary BMD analysis data demonstrated higher femoral/neck values in the HDD group ($p=0.05$).
 - HDD group, % change (0 - 6 mos): 0.54 ± 0.71
 - Placebo group, % change (0 - 6 mos): -1.43 ± 0.66

Rastelli A et al. SABCS 2009;Abstract 803.

Research
To Practice®

Conclusions

- High-dose vitamin D may significantly improve anastrozole-induced MS pain.
 - The beneficial effect of high-dose vitamin D appears to end once vitamin D is supplemented monthly instead of weekly (data not shown).
- Femoral/Neck BMD appears to be maintained at 6 mos in patients administered high-dose vitamin D supplementation.
- High-dose vitamin D was well tolerated and did not cause toxicity.
- Larger studies will be needed to confirm the pilot data presented in this study.

Rastelli A et al. SABCS 2009;Abstract 803.

Research
To Practice®